At-risk mental state: Management

The Recognition and Management of Early Psychosis: A Preventive Approach, Second Edition

Volumn 9780521617314, Issue , 2009, Pages 107-122

  Phillips, Lisa J ^a   Addington, Jean ^b   Morrison, Anthony P ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954705302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576287.008     Document Type: Chapter

References (103)

1. Addington, J. & Addington, D. (2005). Clinical trials during the prodromal stage of schizophrenia. [Letter to the editor.] American Journal of Psychiatry, 162, 1387.
2. Addington, J. & Burnett, P. (2004). Working with families in the early stages of psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 99-116.
3. Addington, J., Francey, S. M. & Morrison, A. P. (2006). Working With People at High Risk of Developing Psychosis: A Treatment Handbook. Chichester, UK: John Wiley.
4. Agerbo, E., Byrne, M., Eaton, W. W. & Mortensen, P. B. (2003). Schizophrenia, marital status and employment: a forty year study. Schizophrenia Research, 60(Suppl 1), 32.
5. Andreasen, N. C. (1987). Creativity and mental illness: prevalence rates in writers and their first-degree relatives. American Journal of Psychiatry, 144, 1288-92.
6. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
7. Barrowclough, C., Haddock, G., Tarrier, N. et al. (2001). Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158, 1706-13.
8. Bechdolf, A., Phillips, L. J., Francey, S. et al. (2006). Recent approaches to psychological interventions for people at risk of psychosis. European Archives of Psychiatry and Neuroscience, 256, 159-73.
9. Beck, A. T. (1976). Cognitive Therapy and the Emotional Disorders. New York: International Universities Press.
10. Beck, A.T., Rush, A.J., Shaw, B.F. & Emery, G. (1979). Cognitive Therapy of Depression. New York: Guilford Press.
11. Bentall, R. P. & Morrison, A. P. (2002). More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. Journal Of mental Health, 11, 351-6.
12. Bernstein, D. A. & Borkovec, T. D. (1973). Progressive Relaxation Training: A Manual for the Health Professionals. Campaign, IL: Research Press.
13. Broome, M. R., Woolley, J. B., Johns, L. C. et al. (2005). Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry, 20, 372-8.
14. Cadenhead, K. (2002). Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics and the identification of the schizophrenia prodrome. Psychiatric Clinics Of north America, 25, 837-53.
15. Carbone, S., Harrigan, S., McGorry, P. D., Curry, C. & Elkins, K. (1999). Duration of untreated psychosis and 12 month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatrica Scandinavica, 100, 96-104.
16. Caroff, S.N., Mann, S.C., Campbell, E.C. & Sullivan, K.A. (2002). Movement disorders associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry, 63(Suppl 4), 12-19.
17. Chadwick, P., Birchwood, M. & Trower, P. (1996). Cognitive Therapyfor Delusions, Voices and Paranoia. Chichester, UK: John Wiley.
18. Corcoran, C., Malaspina, D. & Hercher, L. (2005). Prodromal interventions for schizophrenia vulnerability: the risks of being ‘at risk’. Schizophrenia Research, 73, 173-84.
19. Cornblatt, B. A., Lencz, T. & Kane, J. M. (2001). Treatment of the schizophrenia prodrome: is it presently ethical? Schizophrenia Research, 51, 31-8.
20. Deegan, P. E. (1988). Recovery: the lived experience of rehabilitation. Psychosocial Rehabilitation Journal, 11, 11-19.
21. Deffenbacher, J. L. & McKay, M. (2000). Overcoming Situational and General Anger: A Protocol for the Treatment of Anger Based on Relaxation, Cognitive Restructuring, and Coping Skills Training. Oakland, CA: New Harbinger.
22. Eder-Ischia, U., Ebenbichler, C. & Fleischhacker, W. W. (2005). Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essential Psychopharmacology, 6, 112-17.
23. Elkins, K., Hinton, M. & Edwards, J. (2004). Cannabis and psychosis: a psychological intervention. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 137-56.
24. Falzer, P. R., Stayner, D. A. & Davidson, L. (2004). Principles and strategies for developing psychosocial treatments for negative symptoms in early course psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 229-43.
25. Fowler, D., Garety, P. & Kuipers, E. (1995). Cognitive Behaviour Therapy for Psychosis: Theory and Practice. Chichester, UK: John Wiley.
26. French, P. & Morrison, A. P. (2004). Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach. New York: John Wiley.
27. Germer, C. K., (2005). Anxiety disorders: befriending fear. In C. K. Germer, R. D. Siegel & P. R. Fulton (eds.), Mindfulness and Psychotherapy. New York: Guilford Press, pp. 152-72.
28. Häfner, H., Nowotny, B., Loffler, W., van der Heiden, W. & Maurer, K. (1995a). When and how does schizophrenia produce social deficits? European Archives of Psychiatry and Clinical Neuroscience, 246, 17-28.
29. Häfner, H., Maurer, W., Loffler, B. et al. (1995b). Onset and early course of schizophrenia. In H. Häfner & W. F. Gattaz. (eds.), Causes of Schizophrenia, vol. III. New York: Springer, pp. 43-66.
30. Häfner, H., Maurer, K., Ruhrmann, S. et al. (2004). Are early detection and secondary prevention feasible? Facts and visions. European Archives of Psychiatry and Clinical Neuroscience, 254, 117-28.
31. Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. S. (2006). Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophrenia Bulletin, 32, 166-78.
32. Harrigan, S. M., McGorry, P. D. & Krstev, H. (2003). Does treatment delay in first-episode psychosis really matter? Psychological Medicine, 33, 97-110.
33. Harris, M. G., Henry, L. P., Harrigan, S. M. et al. (2005). The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophrenia Research, 79, 85-93.
34. Hawkins, K.A., McGlashan, T.H., Quinlan, D. et al. (2004). Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research, 68, 339-47.
35. Huber, G. & Gross, G. (1989). The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Progress in Medicine, 80, 646-52.
36. International Early Psychosis Association Writing Group (2005). International clinical practice guidelines for early psychosis. British Journal of Psychiatry, 187(Suppl 48), s120-4.
37. Jablensky, A. & Eaton, W. W. (1995). Schizophrenia. In A. Jablensky (eds.), Epidemiological Psychiatry. London: Bailliere Tindall, pp. 283-306.
38. Jablensky, A., Sartorius, N., Ernberg, G. et al. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine - Monograph Supplement, 20, 1-97.
39. Jayaram, M. B., Hosalli, P. & Stroup, S. (2006). Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, 2, CD005237.
40. Johns, L. C. & van Os, J. (2001). The continuity of psychotic experiences in the general population. Clinical Psychology Review, 21, 1125-41.
41. Kane, J. M. (2004). Tardive dyskinesia rates with atypical anti- psychotics in adults: prevalence and incidence. Journal of Clinical Psychiatry, 65(Suppl 9), 16-20.
42. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-9.
43. Kingdon, D. & Turkington, D. (1994). Cognitive-Behavioural Therapy for Schizophrenia. Hove, England: Lawrence Erlbaum.
44. Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D. & Kollack-Walker, S. (2005). Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. Journal of Clinical Psychopharmacology, 25, 255-8.
45. Klosterkotter, J., Hellmich, M., Steinmeyer, E. M. & Schultze- Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives Of general Psychiatry, 58, 158-64.
46. Larsen, T. K. (2002). The transition from the premorbid period to psychosis: how can it be described? Acta Psychiatrica Scandinavica, 106(Suppl 413), S10-11.
47. Lencz, T., Smith, C. W., Auther, A., Correll, C. U. & Cornblatt, B.A. (2003). The assessment of ‘prodromal schizophrenia’: unresolved issues and future directions. Schizophrenia Bulletin, 29, 717-28.
48. Lieberman, J.A., Tollefson, G.D., Schulz, C. et al. For the HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361-70.
49. Manji, H.K., Moore, G.J. & Chen, G. (2000). Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biological Psychiatry, 48, 740-54.
50. Margolese, H. C., Chouinard, G., Kolivakis, T. T. et al. (2005). Tardive dyskinesia in the era of typical and atypical antipsy- chotics. Part 2: incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry, 50, 703-14.
51. Mason, O., Startup, M., Halpin, S. et al. (2004). Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophrenia Research, 71, 227-37.
52. McFarlane, W. R., Dixon, L., Lukens, E. & Lucksted, A. (2003). Family psychoeducation and schizophrenia: a review of the literature. Journal of Marital and Family Therapy, 29, 223-45.
53. McGlashan, T. H. (2001). Psychosis treatment prior to psychosis onset: ehical issues. Schizophrenia Research, 51, 47-54.
54. McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophrenia Research, 61, 7-18.
55. McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790-9.
56. McGorry, P. D. (2005). Early intervention in psychotic disorders: beyond debate to solving problems. British Journal of Psychiatry, 187(Suppl 48), s108-10.
57. McGorry, P.D., Yung, A.R. & Phillips, L.J. (2001). Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research, 51, 17-29.
58. McGorry, P. D., Yung, A. R., Phillips, L. J. et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921-8.
59. Meichenbaum, D. H. (1975). Self-instructional methods. In F. H. Kanfer & Goldstein, A. P. (eds.), Helping People Change: A Textbook of Methods. New York: Pergamon, pp. 357-91.
60. Meyer, S.E., Bearden, C.E., Lux, S.R., et al. (2005). The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. Journal Of child and Adolescent Psychophar- macology, 15, 434-51.
61. Miller, L.J., O’Connor, E. & DiPasquale, T. (1993). Patients’ attitudes toward hallucinations. American Journal of Psychiatry, 150, 584-8.
62. Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry, 159, 863-5.
63. Miller, T. J., Zipursky, R. B., Perkins, D. et al. (2003a). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II Baseline characteristics of the ‘prodromal’ sample. Schizophrenia Research, 61, 19-30.
64. Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2003b). Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin, 29, 703-15. [Erratum in Schizophrenia Bulletin (2004) 30, 217f.]
65. Miller, W. R. & Rollnick, S. (1991). Motivational Interviewing: Preparing People to Change Addictive Behaviour. New York: Guilford Press.
66. Morrison, A. P. (2001). The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behavioural and Cognitive Psychotherapy, 29, 257-76.
67. Morrison, A.P., French, P., Walford, L. et al. (2004). Cognitive therapy for the prevention of psychosis in people at ultrahigh risk. British Journal of Psychiatry, 185, 291-7.
68. Morrison, A.P., Gumley, A.I., Schwannauer, M. et al. (2005). The beliefs about paranoia scale: preliminary validation of a metacognitive approach to conceptualising paranoia. Behavioural and Cognitive Psychotherapy, 33, 153-64.
69. Morrison, A. P., French, P., Parker, S. et al. (2007). Three year follow-up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra-high risk. Schizophrenia Bulletin, 33, 682-7.
70. Nemeroff, C. B. (2005). Use of atypical antipsychotics in refractory depression and anxiety. Journal of Clinical Psychiatry, 66, 13-21.
71. Newcomer, J. W. (2005). Second-generation (atypical) antipsy- chotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1-93.
72. Norman, R. M. G., Lewis, S. W. & Marshall, M. (2005). Duration of untreated psychosis and its relationship to clinical outcome. British Journal of Psychiatry, 187(Suppl 48), s19-23.
73. O’Reilly, T., Dunbar, R. & Bentall, R. (2001). Schizotypy and creativity: an evolutionary connection? Personality and Individual Differences, 31, 1067-78.
74. Ost, L. G. (1987). Applied relaxation: description of a coping technique and review of controlled studies. Behaviour Research and Therapy, 25, 397-410.
75. Phillips, L. J. & Francey, S. M. (2004). Changing PACE: psychological interventions in the pre-psychotic phase. In J. F. M Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis: A Practical Treatment Handbook. Chichester, UK: John Wiley, pp. 23-40.
76. Phillips, L. J., McGorry, P. D., Yuen, H. P. et al. (2007). Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research, 96, 25-33.
77. Post, S. G. (2001). Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophrenia Research, 51, 103-8.
78. Ramel, W., Goldin, P. R., Carmona, P. E. & McQuaid, J. R. (2004). The effects of mindfulness meditation on cognitive processes and affect in patients with past depression. Cognitive Therapy and Research, 28, 433-55.
79. Read, J. & Harre, N. (2001). The role of biological and genetic causal beliefs in the stigmatisation of ‘mental patients’. Journal of Mental Health, 10, 223-35.
80. Read, J. & Haslam, H. (2004). Public opinion: bad things happen and can drive you crazy. In J. Read, L. R. Mosher & R. P. Bentall (eds.), Models Of madness: Psychological, Social and Biological Approaches to Schizophrenia. Hove, UK: Brunner- Routledge, pp. 133-45.
81. Roemer, L. & Orsillo, S. M. (2002). Expanding our conceptualization of and treatment for generalized anxiety disorder: integrating mindfulness/acceptance-based approaches with existing cognitive-behavioral models. Clinical Psychology: Science and Practice, 9, 54-68.
82. Ruhrmann, S., Schultze-Lutter, F. & Klosterkotter, J. (2003). Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 36(Suppl 3), S162-7.
83. Ryle, A. & Kerr, I. B. (2002). Introducing Cognitive Analytic Therapy: Principles and Practice, Chichester, UK: John Wiley.
84. Sachdev, P. S. (2005). Neuroleptic-induced movement disorders: an overview. Psychiatric Clinics of North America, 28, 255-74.
85. Siddle, R. & Haddock, G. (2004). Cognitive-behavioural therapy for acute and recent-onset psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 41-62.
86. Stathis, S., Martin, G. & McKenna, J. G. (2005). A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. Journal Of clinical Psychopharmacology, 25, 539-44.
87. Sullivan, H. S. (1927; reprinted 1994). The onset of schizophrenia. American Journal of Psychiatry, 151, 135-9.
88. Svirkis, T., Korkeila, J., Heinimaa, M. et al. (2005). Axis I disorders and vulnerability to psychosis. Schizophrenia Research, 75, 439-46.
89. Tarrier, N., Harwood, S., Yusopoff, L., Beckett, R. & Baker, S. (1990). Coping strategy enhancement (CSE): a method of treating residual schizophrenic symptoms. Behavioural Psychotherapy, 18, 283-93.
90. Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M. & Slooff, C. J. (2005). Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. British Journal of Psychiatry, 186, 324-30.
91. Warner, R. (1985). Recovery from Schizophrenia: Psychiatry and Political Economy. New York: Routledge & Kegan Paul.
92. Warner, R. (2003). How much of the burden of schizophrenia is alleviated by treatment? British Journal of Psychiatry, 183, 375-6.
93. Warner, R. (2005). Problems with early and very early intervention in psychosis. British Journal of Psychiatry, 187(Suppl 48), s104-7.
94. Woods, S., Zipursky, R., Perkins, D. et al. (2002). Olanzapine vs. placebo for prodromal symptoms. Acta Psychiatrica Scandinavica, 106(Suppl 413), 43.
95. Woods, S. W., Breier, A., Zipursky, R. B. et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453-64.
96. Wykes, T. & van der Gaaz, M. (2001). Is it time to develop a new cognitive therapy for psychosis: cognitive remediation therapy (CRT). Clinical Psychology Review, 21, 1227-56.
97. Yung, A. R. & McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin, 22, 353-70.
98. Yung, A. R. & McGorry, P. D. (2003). Keeping an open mind: investigating options for treatment options of the pre-psychotic phase. Journal of Mental Health, 12, 341-3.
99. Yung, A. R., Phillips, L. J. & McGorry, P. D. (2004). Treating Schizophrenia in the Prodromal Phase. London: Taylor & Francis.
100. Yung, A. R., Phillips, L. J., Yuen, H. P. et al. (2003). Psychosis prediction: 12 month follow-up of a high risk (‘prodromal’) group. Schizophrenia Research, 60, 21-32.
101. Yung, A. R., Yuen, H. P., McGorry, P. D. et al. (2005). Mapping the onset of Psychosis: the Comprehensive Assessment of At Risk Mental States (CAARMS). Australian and New Zealand Journal of Psychiatry, 39, 964-71.
102. Zimmermann, G., Favrod, J., Trieu, V. H. & Pomini, V. (2005). The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia-spectrum disorders: a metaanalysis. Schizophrenia Research, 77, 1-9.
103. Zubin, J. & Spring, B. (1977). Vulnerability: a new view of schizophrenia. Journal of Abnormal Psychology, 86, 103-26.